Yazar "Yaman, Emel" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    Non-Urothelial Bladder Cancer: Comparison of Clinicopathological and Prognostic Characteristics in Pure Adenocarcinoma and Non-Bilharzial Squamous Cell Carcinoma of the Bladder
    (Karger, 2018) Erdem, Gokmen U.; Dogan, Mutlu; Sakin, Abdullah; Oruc, Zeynep; Yaman, Emel; Cinkir, Havva Yesil; Uysal, Mukremin
    Objectives: The clinicopathological characteristics, treatment modalities, and effects on the prognosis of pure squamous cell carcinoma (SqCC) and adenocarcinoma (AC) were evaluated. Materials and Methods: 86 patients with pure SqCC and AC bladder cancer were evaluated retrospectively. Results: Of the 86 patients, 51 had SqCC and 35 had AC. No differences in clinicopathological characteristics were observed between patients with AC and SqCC, except for the prevalence of T4 disease (28.6% vs. 51.0%, respectively). In multivariate analysis, older age, stage IV disease, and Eastern Cooperative Oncology Group (ECOG) performance status (> 2) were predictive of a poor overall survival (OS). The median OS was significantly longer for stage I-III patients (82.9 months) treated with surgery +/- chemotherapy (CT) +/- radiotherapy (RT) than for those treated with transurethral resection +/- CT +/- RT (24.3 months) (P = 0.007). The median OS of patients with SqCC and AC who were given platinum-based CT for metastasis was 7.7 and 30.3 months, respectively. Conclusions: Advanced age, stage IV disease, and poor ECOG performance status were factors associated with a poor prognosis. Surgery +/- CT +/- RT resulted in significantly better OS, except in stage IV disease. Patients with metastatic AC had better response rates with platinum- based CT. (c) 2018 S. Karger GmbH, Freiburg
  • [ X ]
    Öğe
    Prognostic significance of serum matrix metalloproteinase 9 (MMP-9) levels in patients with sarcomas
    (Akad Doktorlar Yayinevi, 2008) Yaman, Emel; Yalcin, Buelent; Utkan, Guengoer; Akbulut, Hakan; Isikdogan, Abdurrahman; Sencan, Orhan; Buyukcelik, Abdullah
    Sarcomas are heterogeneous groups of tumors that are seen rarely. Although great efforts have been made to identify prognostic factors apart from grade, histology and tumor size, they're not so obvious yet. In this study, the prognostic role of serum matrix metalloproteinase (MMP)-9 levels in patients with sarcoma was evaluated. Eighty-eight patients with a diagnosis of sarcoma were included in the study. Additionally in 14 patients with osteosarcoma, serum MMP-9 levels were analyzed twice. one in preoperative period during neoadjuvant chemotherapy and one in postoperative period. Sixteen healthy volunteers composed the control group. Serum MMP-9 levels have been evaluated quantitively by ELISA method. Serum MMP-9 levels were higher significantly compared to control group (p < 0.005). Patients with metastatic disease have higher serum MMP-9 levels compared to the non-metastatic ones which were statistically non-significant (p: 0.9). Similarly, no difference in serum MMP-9 levels was observed between patients with intermediate-high grade tumors and with low grade tumors. Moreover, statistically significant decrease in serum MMP-9 levels was observed in patients in postoperative period compared to preoperative period (p: 0.016). Although this study was performed in small number and heterogeneous group of patients, the difference in serum MMP-9 levels between sarcoma patients and control group, especially in the presence of measurable lesions and in postoperative period of the same patients, suggests that serum MMP-9 levels may be used as a tumor marker in patients with sarcoma.
  • [ X ]
    Öğe
    Prognostic significance of serum matrix metalloproteinase 9 (MMP-9) levels in patients with sarcomas
    (2008) Işıkdoğan, Abdurrahman; İçli, Fikri; Şencan, Orhan; Yaman, Emel; Utkan, Güngör; Yalçın, Bülent; Pamir, Ali
    Sarkomlar oldukça nadir olarak gözlenen heterojen bir tümör grubudur. Tüm çabalara karşın tümor histolojisi, greydi ve tümör boyutu dışında bir prognostik faktör tayin edilememiştir. Bu calışmada sarkomlu hastalarda serum matriks metalloproteinaz-9 (MMP-9) duzeyinin prognostik değeri araştırıldı.Çalışmaya histopatolojik olarak sarkom tanısı konulmuş olan 88 hasta alındı. Osteosarkom tanılı 14 hastada serum MMP-9 düzeyi operasyon öncesinde neoadjuvant kemoterapi döneminde 1 kez ve postoperative dönemde 1 kez olmak üzere iki kez örneklendi. Onaltı sağlıklı gönüllü kontrol grubunu oluşturdu. Serum MMP-9 düzeyleri ELISA yöntemi ile ölçüldü.Serum MMP-9 düzeyleri sarkomlu hastalarda kontrol grubuna göre anlamlı oranda yüksek bulundu (p<0.005). Metastatik hastalık varlığında istatiksel öneme ulaşmayan bir yükseklik saptandı (p: 0.9). Benzer şekilde orta-yüksek greydli tümörü olanlarla düşük greydli tümörü olan hastalar arasında serum MMP-9 düzeyleri arasında anlamlı bir farklılık gözlenmedi. En önemlisi, serum MMP-9 düzeyleri açısından postoperatif dönemde yapılan örneklemelerde peraoperatif sürece göre anlamlı oranda azalma saptandı (p: 0.016).Her ne kadar bu çalışma sınırlı sayıda ve heterojen bir grup hastayı içerse de sarkomlu hastalar ile kontrol grubu arasında, özellikle aynı hastaların preoperatif ve postoperatif dönem serum MMP-9 düzeyleri arasındaki farklılık serum MMP-9 düzeylerinin sarkomlu hastaların takibinde faydalı olabilecek bir belirteç olabileceğini düşündürmektedir.